The Glaucoma Drugs Clinical Pipeline 2021​


​Release Date: Q4' 2021
Number of Candidates: 55

Synopsis: Often cited as the leading cause of irreversible blindness worldwide, glaucoma is a complex eye disease in which damage to the optic nerve leads to progressive, permanent vision loss. Although this damage is usually caused by increased IOP (Intraocular Pressure) inside the eye, even patients with normal range IOP can develop glaucoma.

Glaucoma can be treated with eye drops, injections, oral pills, laser treatment or surgery. Expected to surpass $10 Billion in global spending by the end of 2021, drugs remain the preferred approach to treat most cases of glaucoma. The market is ripe for future growth with three recent approvals of new drug classes, and a number of novel therapies in late-stage development. The glaucoma pipeline also includes fixed dose combinations (FCs), which have the potential for improving patient adherence while decreasing exposure of preservatives to the eye.

The Glaucoma drug development pipeline excel sheet features 55 candidates spanning 10 classifications in active development. 

For a Sample and Inquiries please contact [email protected]

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 1000

Company Wide License (Single Site): USD 1,500

Company Wide License (Global Site): USD 2,500

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories: 
  • Candidate Name
  • Drug Developer(s)
  • Phase(s)
    • ​Phase I/II
    • Phase II
    • Phase III
    • Pre-Clinical
    • Pre-Registration 
    • Research
  • Classification ​​
    • ​Beta-adrenergic receptor antagonists
    • Cannabinoid-Based Therapies
    • Gene & Cell Therapies
    • New Delivery Mechanisms for Existing Drugs
    • Nitric Oxide Donors
    • Prostaglandin EP2, EP3 & FP Receptor Agonists
    • ROCK Inhibitors
    • siRNA (Small interfering RNA)
    • Tie-2 Pathway Activators
    • Others